Cutaneous candidosis in immunosuppressed patients
Language English Country United States Media print
Document type Journal Article
PubMed
11830950
DOI
10.1007/bf02815627
Knihovny.cz E-resources
- MeSH
- Antifungal Agents therapeutic use MeSH
- Candida classification pathogenicity MeSH
- Phagocytosis MeSH
- Antigen-Antibody Complex blood MeSH
- Immunocompromised Host * MeSH
- Candidiasis, Cutaneous drug therapy immunology MeSH
- Humans MeSH
- Antibodies, Fungal blood MeSH
- Risk Factors MeSH
- T-Lymphocytes immunology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Antifungal Agents MeSH
- Antigen-Antibody Complex MeSH
- Antibodies, Fungal MeSH
One-hundred patients with candidosis of the skin, mucous membranes and nail plates (confirmed by cultivation) were examined. Topical or systemic antimycotic treatment was successful in 58 patients. After a complete evaluation, 42 patients were found to suffer from factors supporting candidosis--diabetes mellitus (12), anemia (3) and various local factors (10 patients); 27 patients showed a deficiency in cell-mediated immunity. In addition to intensive antimycotic therapy, successful treatment is affected by the actual immunity level and can be ensured by efficient immunomodulation treatment of immunodeficiency.
See more in PubMed
Pediatr Infect Dis J. 1998 Sep;17(9):819-22 PubMed
Folia Microbiol (Praha). 2001;46(4):333-7 PubMed
Mycoses. 1998 May-Jun;41(5-6):219-21 PubMed
Folia Microbiol (Praha). 2000;45(6):561-5 PubMed
Folia Microbiol (Praha). 2000;45(4):369-72 PubMed
Folia Microbiol (Praha). 2000;45(4):364-8 PubMed
Incidence of Candida species isolated from human skin and nails: a survey
